Key player in Pershing Square's Valeant bet leaving firm
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Valeant (VRX) Derm NRx Up 1% Week-Over-Week, ophth NRx Down 5.1% - RBC
May 13, 2016 12:48 PM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 1.0% WoW, ophth NRx were down 5.1% WoW, and Addyi NRx were down 3.6% WoW.
Miehm commented, "For the week ending May 6th, new derm scripts (NRx) were up 1.0% vs. up 2.2% the prior... More



